about
Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma.Expression profile of SIRT2 in human melanoma and implications for sirtuin-based chemotherapy.Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance.Management of intracranial melanomas in the era of precision medicine.SIRT6 histone deacetylase functions as a potential oncogene in human melanoma.Management of the cutaneous adverse effects of antimelanoma therapy
P2860
Q37689374-EB9E9A9B-8810-4E4F-A835-C04F4FC8D6FDQ38595251-5E49A8E7-0EF3-493D-AEC9-29142C34A549Q38717695-C253F9D0-E65E-4CE1-88F2-FC79E810D884Q40934119-E3918C04-B4CD-4A52-86D0-0975B6CA65B5Q44959749-D9248E55-4E5D-4F3A-BD48-E6DF9306DC76Q47116393-CF8972CE-529D-4952-A2ED-5B2D43D51A15Q56893430-37905B56-1C60-4DCD-AD6C-B642528B9B50
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Managing the skin toxicities from new melanoma drugs.
@en
type
label
Managing the skin toxicities from new melanoma drugs.
@en
prefLabel
Managing the skin toxicities from new melanoma drugs.
@en
P2860
P1476
Managing the skin toxicities from new melanoma drugs.
@en
P2093
John C Mavropoulos
Timothy S Wang
P2860
P2888
P304
P356
10.1007/S11864-014-0284-6
P577
2014-06-01T00:00:00Z
P6179
1053207296